Gruppo Italiano Terapie Innovative nei Linfomi
Quick facts
Phase 3 pipeline
- Rituximab-HDS · Oncology
Rituximab-HDS is a high-dose formulation of rituximab, a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gruppo Italiano Terapie Innovative nei Linfomi portfolio CI brief
- Gruppo Italiano Terapie Innovative nei Linfomi pipeline updates RSS
Frequently asked questions about Gruppo Italiano Terapie Innovative nei Linfomi
What is Gruppo Italiano Terapie Innovative nei Linfomi's pipeline?
Gruppo Italiano Terapie Innovative nei Linfomi has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Rituximab-HDS.
Related
- Sector hub: All tracked pharma companies